

Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Monomer Protein

Cat. No. MHC-HM427

Description

| | |
|-------------------------|--|
| Source | Recombinant Human MAGE-A3(HLA-A*01:01) Protein is expressed from HEK293 with His tag and Avi Tag at the C-Terminus. It contains Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and EVDPIGHLY peptide. |
| Accession | Q5SUL5(HLA-A*01:01)&P61769(B2M)&EVDPIGHLY |
| Molecular Weight | The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result. |
| Endotoxin | Less than 1EU per µg by the LAL method. |
| Purity | > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |

Formulation and Storage


| | |
|-----------------------|---|
| Formulation | Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage | -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |

Background

Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.

Assay Data


Bis-Tris PAGE



Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Monomer is greater than 95% as determined by SEC-HPLC.